AbbVie Inc. Research and Development (R&D) Expenses Growth

Research and Development (R&D) Expenses Growth of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development (R&D) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development (R&D) Expenses Growth for the quarter ending December 30, 2019 was -76.26% (a -195.08% decrease compared to previous quarter)
  • Year-over-year quarterly Research and Development (R&D) Expenses Growth decreased by -2206.63%
  • Annual Research and Development (R&D) Expenses Growth for 2019 was -37.97% (a -135.72% decrease from previous year)
  • Annual Research and Development (R&D) Expenses Growth for 2018 was 106.29% (a 649.58% increase from previous year)
  • Annual Research and Development (R&D) Expenses Growth for 2017 was 14.18% (a 508.58% increase from previous year)
  • Twelve month Research and Development (R&D) Expenses Growth ending December 30, 2019 was -37.97% (a -132.53% decrease compared to previous quarter)
  • Twelve month trailing Research and Development (R&D) Expenses Growth decreased by -136.85% year-over-year
Trailing Research and Development (R&D) Expenses Growth for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
-37.97% 116.71% 98.83% 103.05%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development (R&D) Expenses Growth of AbbVie Inc.

Most recent Research and Development (R&D) Expenses Growthof ABBV including historical data for past 10 years.

Interactive Chart of Research and Development (R&D) Expenses Growth of AbbVie Inc.

AbbVie Inc. Research and Development (R&D) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 -76.26% 80.21% -2.34% 3.62% -37.97%
2018 361.29% 3.26% 7.57% 8.93% 106.29%
2017 16.46% 11.03% 9.34% 20.72% 14.18%
2016 12.47% -22.0% 14.58% 16.65% 2.33%
2015 22.3% 74.63% 17.63% 5.05% 29.97%
2014 10.15% 13.73% 17.63% 21.77% 15.48%
2013 17.18% -12.18% 10.44% -1.25% 2.77%
2012 -73.84% 0.0% 0.0% 9.35% 6.11%
2011 4.93%
2010 46.13%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.